Microacidophilus oligotrophic monocytogenes capable of improving alcoholic cardiomyopathy and its application

The lack of microbial preparations in the treatment of alcoholic cardiomyopathy was solved by using the use of micro-eosinophila Stenotrophomonas acidamineiphila and its related products, achieving a significant reduction in the symptoms of alcoholic cardiomyopathy, including myocardial injury and myocardial hypertrophy, providing A new treatment direction.

CN117106669BActive Publication Date: 2024-12-03ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311268400.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-28
Publication Date
2024-12-03
Estimated Expiration
2043-09-28

AI Technical Summary

Technical Problem

Microbial preparations for alcoholic cardiomyopathy are lacking in the prior art, and micro-eosinophilus is rarely reported in this field.

Method used

提供一种微嗜酸寡养单胞菌Stenotrophomonas acidaminiphila CGMCC No.26919及其相关产物,包括发酵液、灭活菌体和菌悬液,用于制备改善酒精性心肌病和降血糖的药物,通过接种至LB液体培养基并在37℃扩大培养18~24小时。

Benefits of technology

This micro-eosinophila significantly reduces the plasma creatine kinase isoenzyme (CK-MB) content caused by alcohol, restores the left ventricular ejaculation fraction and the shortening of the left ventricular short axis, inhibits myocardial hypertrophy, and reduces myocardial injury. It has the function of improving alcoholic cardiomyopathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117106669B_ABST
    Figure CN117106669B_ABST
Patent Text Reader

Abstract

The present invention discloses microacidophilic oligotrophic mononas and its application for improving alcoholic cardiomyopathy, and belongs to the field of microbial technology. The above-mentioned microacidophilic oligotrophic mononas (Stenotrophomonas acidaminiphila), its deposit number is CGMCCNo.26919. It was found through experimental verification that the microacidophilic oligotrophic mononas has a regulatory effect on the increase of creatine kinase isoenzyme (CK-MB) content in plasma caused by alcohol, the decrease of left ventricular ejection fraction and the decrease of left ventricular short axis shortening rate, the increase of left ventricular posterior wall thickness during diastole and systole, the increase of heart weight, the decrease of myocardial cell Bcl2mRNA level, the increase of BaxmRNA level, etc., and then protects the myocardium from myocardial damage. Therefore, the microacidophilic oligotrophic mononas disclosed in the present invention can effectively alleviate the myocardial damage caused by alcohol and improve alcoholic cardiomyopathy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, in particular to oligotrophic microacidiotrophs capable of improving alcoholic cardiomyopathy and application thereof. Background Art

[0002] Alcohol intake is one of the main causes of cardiovascular disease. Long-term heavy drinking can lead to alcoholic cardiomyopathy (ACM). Clinical manifestations include low left ventricular ejection fraction, ventricular dilation, and development of congestive heart failure. Drug treatment should include targeted heart failure treatment for idiopathic dilated cardiomyopathy with reduced ejection fraction, including beta-blockers, angiotensin-converting enzyme inhibitors, diuretics, aldosterone receptor antagonists, and angiotensin blocker-neprilysin inhibitor combinations (if LVEF is less than or equal to 40%). Most of the drugs with the above functions are chemically synthesized drugs, and there are few reports on drugs with microbial preparations.

[0003] The currently known use of Stenotrophomonas acidaminiphila is to degrade various compounds. For example, the invention "Application of Stenotrophomonas acidaminiphila in Degrading Ethylbenzene" with patent number CN115725449A discloses that a strain of Stenotrophomonas acidaminiphila JPEB-1 can degrade ethylbenzene under inorganic salt culture conditions, and can achieve biodegradation of high-concentration ethylbenzene in combination with Micrococcus luteus JPEB-2. The invention "A Pyrethroid Insecticide Degradation Strain and Its Application" with patent number CN110577908A discloses that the strain of Stenotrophomonas acidaminiphila ZH-01 can effectively degrade pyrethroid insecticides such as bifenthrin in a short period of time, and has a significant biodegradation effect. Patent No. CN110591980A, "A microbial composite agent for degrading high-coagulation oil and its application", discloses: A microbial composite agent containing Stenotrophomonas acidaminiphila can be used to degrade high-coagulation oil. Patent No. CN106967641A, "A microbial oligotrophic bacterium and its application", discloses: Stenotrophomonas acidaminiphila SP-3 is used to degrade azo dye wastewater.

[0004] Although Microacidophilus Stenotrophomonas has multiple functions, there are currently no reports on the use of Microacidophilus Stenotrophomonas in the treatment of alcoholic cardiomyopathy. Summary of the invention

[0005] The purpose of the present invention is to provide a microacidophilic oligotrophic mononas and its application for improving alcoholic cardiomyopathy, so as to solve the problems existing in the above-mentioned prior art. The strain can significantly improve alcoholic cardiomyopathy, protect myocardial damage, and provide a new direction for the relief and improvement of alcoholic cardiomyopathy.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides a microacidophilic oligotrophic mononas (Stenotrophomonas acidaminiphila), the microacidophilic oligotrophic mononas preservation number is CGMCC No.26919, the preservation time is March 28, 2023, the preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0008] The present invention also provides the use of the microacidophilic oligotrophic monosporus or its related products in the preparation of drugs for improving alcoholic cardiomyopathy. The related products include fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0009] The present invention also provides the use of the microacidophilic oligotrophic monosporus or its related products in the preparation of blood sugar-lowering drugs, and the related products include the fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0010] The present invention also provides a drug for improving alcoholic cardiomyopathy, which contains the microacidophilic oligotrophic monosporus or its related products, wherein the related products include the fermentation liquid, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0011] The present invention also provides a blood sugar lowering drug containing the microacidophilic oligotrophic monosporus or its related products, wherein the related products include the fermentation liquid, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0012] The present invention also provides a fermentation method of the microacidophilic oligotrophic mononas, characterized in that the microacidophilic oligotrophic mononas is inoculated into LB liquid culture medium and expanded and cultured at 37° C. for 18 to 24 hours.

[0013] The present invention discloses the following technical effects:

[0014] The present invention isolates a new strain of microacidophilic oligotrophic monospore from the feces of a six-year-old child. Through experimental verification, it is found that the microacidophilic oligotrophic monospore has a reducing effect on the increase in the content of creatine kinase isoenzyme (CK-MB) in plasma caused by alcohol; it has a restoring and improving effect on the decrease in left ventricular ejection fraction and left ventricular short axis shortening rate caused by alcohol, and restores the myocardial ejection capacity of mice; it has an inhibitory effect on the increase in left ventricular posterior wall thickness during diastole and systole caused by alcohol, and alleviates the symptoms of myocardial hypertrophy; it has an inhibitory effect on the increase in heart weight caused by alcohol, and the HW / BW ratio decreases, which alleviates the symptoms of myocardial hypertrophy; it has a restoring and improving effect on the decrease in myocardial cell Bcl2 mRNA level caused by alcohol; it has an inhibitory effect on the increase in myocardial cell Bax mRNA level caused by alcohol. It can be seen that the microacidophilic oligotrophic monospore disclosed in the present invention can effectively alleviate myocardial damage caused by alcohol and has the function of improving alcoholic cardiomyopathy. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0016] Figure 1 The colony culture characteristics of the microacidophilic oligotrophic mononas ZCMU-Sa01 of the present invention;

[0017] Figure 2 The morphological characteristics of the microacidophilic oligotrophic mononas ZCMU-Sa01 of the present invention observed under a microscope;

[0018] Figure 3 is the electrophoresis test result of 16S rDNA of oligotrophic mononas microacidophilus ZCMU-Sa01 of the present invention; M is a DNA standard molecule, and Sa01 is a DNA amplification product of oligotrophic mononas microacidophilus ZCMU-Sa01;

[0019] Figure 4 The figure shows the effect of ZCMU-Sa01 of the present invention on creatine kinase isoenzyme (CK-MB) in mouse plasma; compared with the control group, # P<0.05; compared with the alcohol group, * P < 0.05;

[0020] Figure 5 The figure shows the change of ZCMU-Sa01 on left ventricular ejection fraction in mice; compared with the control group, # P<0.05; compared with the alcohol group, * P < 0.05;

[0021] Figure 6 The changes of ZCMU-Sa01 on the short axis shortening rate of the left ventricle in mice; compared with the control group, # P<0.05; compared with the alcohol group, * P < 0.05;

[0022] Figure 7 The effect of ZCMU-Sa01 of the present invention on the thickness of the left ventricular posterior wall in the diastolic period of the mouse heart; in the figure, compared with the control group, # P<0.05; compared with the alcohol group, * P < 0.05;

[0023] Figure 8 The effect of ZCMU-Sa01 of the present invention on the thickness of the left ventricular posterior wall during the systolic period in the mouse heart; in the figure, compared with the control group, # P<0.05; compared with the alcohol group, * P < 0.05;

[0024] Fig. 9 The figure shows the effect of ZCMU-Sa01 of the present invention on the heart weight of mice. Compared with the control group, # P<0.05; compared with the alcohol group, * P < 0.05;

[0025] Fig.10 The figure shows the effect of ZCMU-Sa01 of the present invention on the heart-to-body weight ratio of mice. Compared with the control group, # P<0.05; compared with the alcohol group, * P<0.05);

[0026] Fig.11 The figure shows the effect of ZCMU-Sa01 of the present invention on the level of Bcl2 mRNA in the heart of mice. Compared with the control group, # P<0.05; compared with the alcohol group, * P < 0.05;

[0027] Fig.12 The figure shows the effect of Sa01 of the present invention on the level of Bax mRNA in the heart of mice; compared with the control group, # P<0.05; compared with the alcohol group, * P<0.05. DETAILED DESCRIPTION

[0028] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0029] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0030] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0031] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0032] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0033] Example 1 Screening and identification of oligotrophomonas microacidophilus ZCMU-Sa01

[0034] 1. Sample source

[0035] The strain isolated in the present invention was isolated from the feces of a six-year-old child.

[0036] 2. Isolation and purification of strains

[0037] Take out the stored strain from the -80℃ refrigerator and inoculate it onto fresh LB medium at pH 6 by streaking. Invert and incubate in a 37℃ constant temperature incubator for 2-3 days. When a single clone grows out, pick it with an inoculation loop and inoculate it onto fresh LB medium at pH 6 by streaking. After a single clone grows out, store it in a 4℃ refrigerator for later use.

[0038] 3. Identification of Oligotrophomonas microacidophilus ZCMU-Sa01

[0039] 3.1 Colony characteristics

[0040] After the isolated and purified strain was cultured in LB solid medium for 48 hours, the colonies were nearly round, white, uniform in size, with smooth and neat edges without wrinkles, and a moist surface. Figure 1 .

[0041] 3.2 Morphology under microscope

[0042] The colony of the isolated and purified strain was smeared: Gram staining was negative, non-spore-forming, round-ended short rods, single or short chain, Figure 2 .

[0043] 3.3 16S rDNA identification

[0044] The target strain genomic DNA was extracted using the Ezup column bacterial genomic DNA extraction kit, and the extracted strain genomic DNA was used as a template for PCR amplification. The bacterial universal primers 27F and 1492R were used to perform a PCR experiment on 16S rDNA. After the PCR reaction was completed, the PCR product was taken for agarose gel detection and photography. The length of the amplified fragment was about 1.2kbp. The PCR product was sent to Zhejiang Tianke High-tech Development Co., Ltd. for sequencing. The result is shown in SEQ ID NO.1. The BLAST sequence alignment was performed on the NCBI website. The results showed that the sequence had a homology of more than 99% with the 16S rDNA sequence identified by Microacidophilic Oligotrophomonas. The sequence alignment results of the strain were combined with the physiological and biochemical results to determine that the screened strain was Microacidophilic Oligotrophomonas, and it was named Microacidophilic Oligotrophomonas ZCMU-Sa01, see Figure 3 .

[0045] SEQ ID NO.1 is as follows: AGTCGAGC GCAGGAAG CCGTCTGA ACCCTTCG GGGGGACGACGGTGGAATGAGCGG CGGACGGG TGAGTAAC ACGTAAAG AACCTGCC CATAGGTCTGGGATAACCACGAGAAATCGGGG CTAATACC GGATGTGT CATCGGAC CGCATGGT CCGCTGATGAAAGGCG CTCCGGCG TCGCCCAT GGATGGCT TTGCGGTG CATTAGCT AGTTGGTG GGGTAACGGCCCACCAAGGCGACG ATGCATAG CCGACCTG AGAGGGTG ATCGGCCA CACTGGGA CTGAGACACGGCCCAG ACTCCTAC GGGAGGCA GCAGTAGG GAATCTTC CACAATGG ACGAAAGT CTGATGGAGCAACGCC GCGTGAAC GATGAAGG CTTTCGGG TCGTAAAG TTCTGGTG TAAGGGAA GAACAAGTGCCGCAGG CAATGGCG GCACCTTG ACGGTACC TTGCGAGA AAGCCACG GCTAACTA CGTGCCAGCAGCCGCG GTAATACG TAGGTGGC AAGCGTTG TCCGGAAT TATTGGGCGTAAAGCG CGCGCAGGCGGACTCT TAAGTCTG ATGTGAAA GCCCCCGG CTCAACCG GGGAGGGC CATTGGAA ACTGGGAGGCTTGAGT ATAGGAGA GAAGAGTG GAATTCCACGTGTAGC GGTGAAAT GCGTAGAG ATGTGGAGGAACACCAGTGGCGAA GGCGACTC TTTGGCCT ATAACTGA CGCTGAGG CGCGAAAG CGTGGGGAGCAAACAG GATTAGAT ACCCTGGT AGTCCACG CCGTAAAC GATGAGTG CTAGGTGT TGGAGGGTTTCCGCCC TTCAGTGC TGAAGCTA ACGCATTAAGCACTCC GCCTGGGG AGTACGGT CGCAAGGCTGAAACTC AAAGGAAT TGACGGGG ACCCGCACAAGCGGTG GAGCATGT GGTTTAATTCGAAGCAACGCGAAG AACCTTAC CAACTCTT GACATCCCC CTGACCGG TACAGAGATGTAACCTTCCCCTCG GGGGCAGG GGTGACAG GTGGTGCATGGTTGTC GTCAGCTC GTGTCGTG AGATGTTGGGTTAAGT CCCGCAAC GAGCGCCA ACCCTTGT CCTTAGGTT GCCAGCAT TTGGTTGGGCACTCTAGGGAGACT GCCGGTGACAAACCGG AGGAAGGT GGGGATGACGTCAAAT CATCATGC CCCTTATGAGTTGGGC TACACACG TGCTACAA TGGACGGT ACAAAGGG CAGCGAAG CCGCGAGG TGGAGCCAATCCCAGAAAGCCGTT CTCAGTTC GGATTGCA GGCTGCAA CTCGCCTG CATGAAGT CGGAATCGCTAGTAAT CGCAGGTC AGCATACT GCGGTGAA TACGTTCC CGGGTCTT GTACACAC CGCCCGTCACACCACG AGAGTTTG CAACACCC GAAGTCGG TGAGGTAA

[0046] Stenotrophomonas acidaminiphila Sa01 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on March 28, 2023, with the deposit number: CGMCC No.26919, and the deposit address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0047] Example 2 Preparation of the bacterial solution of oligotrophomonas microacidophilus ZCMU-Sa01

[0048] The preparation method of ZCMU-Sa01 bacterial solution is as follows: the strain ZCMU-Sa01 stored in the glycerol tube is first activated by streaking on the LB agar plate for 2 to 3 times, and then a single colony is picked and expanded in LB liquid culture medium at 37°C for 18 to 24 hours until the concentration of the bacterial solution reaches 10 9 ~10 10 CFU / mL, as a bacterial suspension (live bacterial solution). In actual use, physiological saline can be used to adjust the bacterial solution to the required concentration, for example, to 5×10 9 CFU / mL.

[0049] Preparation method of inactivated ZCMU-Sa01 bacterial solution: inactivate the above-mentioned ZCMU-Sa01 bacterial suspension at 121° C. under high temperature and high pressure for 30 min to obtain the inactivated ZCMU-Sa01 bacterial solution.

[0050] Example 3: Microacidophilus oligotrophomonas ZCMU-Sa01 improves alcoholic cardiomyopathy

[0051] 1. Materials

[0052] Experimental animals: 20 C57BL / 6 male mice were purchased from Shanghai Slake Experimental Animal Center, company license number: SCXK (Shanghai) 2013-0016, and were kept in the Experimental Animal Center of Zhejiang Chinese Medical University in an SPF environment.

[0053] Reagents: Lieber-DeCarli alcohol liquid model feed (product code TP-4030B, Nantong Trophy Feed Technology Co., Ltd.); Lieber-DeCarli control liquid feed (product code TP-4030D, Nantong Trophy Feed Technology Co., Ltd.); choline, vitamins (Nantong Trophy Feed Technology Co., Ltd.). Anhydrous ethanol (CAS-NO: 64-17-5, lichrosolv), creatine kinase isoenzyme (Lot: N28018610, CUSABIO).

[0054] 2. Experimental methods

[0055] After C57BL / 6 mice were adapted to feeding in an SPF animal laboratory, 8-week-old C57BL / 6 mice were randomly divided into 4 groups, with 8 mice in each group:

[0056] 1) PF group: normal saline group;

[0057] 2) AF group: alcohol liquid feed group;

[0058] 3) AF+Sa01 group: alcohol liquid feed + ZCMU-Sa01 bacterial solution, the bacterial solution contains 10 9 CFU / mL of Sa01 live bacterial solution;

[0059] 4) AF+Sa01 (heat-killed) group: alcohol liquid feed + inactivated ZCMU-Sa01 bacterial solution, the inactivated treatment contained 10 9 CFU / ml of ZCMU-Sa01 live bacterial liquid was treated at 121℃ for 30min.

[0060] The PF group was fed with Lieber-DeCarli control liquid feed for 9 weeks, during which the volume of the control liquid feed of the PF group was adjusted according to the intake of the Lieber-DeCarli alcohol liquid model feed of the AF group; the AF, AF+Sa01, and AF+Sa01 (heat-killed) groups were given Lieber-DeCarli control liquid feed in the first week and Lieber-DeCarli alcohol liquid model feed with a calorie ratio of 24.50% in the second week. Subsequent feeding was shown in Table 1, gradually increasing the volume and calories of alcohol in the feed.

[0061] The liquid feed consumed by mice was replaced with newly prepared feed at 17:00 every day. The weight of mice was recorded every week to detect changes. After 4 weeks, the alcoholic cardiomyopathy model was successfully established. Mice were anesthetized by intraperitoneal injection of 10% chloral hydrate, blood was taken from the apex of the heart to determine creatine kinase isoenzyme (CK-MB), and part of the mouse heart tissue was fixed with 4% paraformaldehyde for tunnel staining.

[0062] 3. Feed formula

[0063] Preparation method of liquid feed used in experimental mice:

[0064] Table 1 Liquid feed formula for the mouse chronic alcohol model (1L)

[0065]

[0066]

[0067] Add about 600 mL of water, stir until completely dissolved, and then add water to make up to 1 L.

[0068] Note: The main ingredients of the feed were purchased from Nantong Trofi Feed Technology Co., Ltd., mainly including casein, L-cystine, DL-methionine, corn oil, olive oil, safflower oil, cellulose, minerals, vitamins, choline bitartrate, xanthan gum, and TBHQ.

[0069] 4. Index determination

[0070] 4.1 Plasma CK-MB detection

[0071] Take mouse plasma samples and collect whole blood into tubes containing anticoagulants. EDTA sodium salt is recommended as the anticoagulant. Centrifuge at 1000×g for 15 minutes within 30 minutes after sample collection and take the supernatant. 100 μL of standard working solution and test sample were added to each reaction well. The standard needed to be repeated. After sealing the plate, incubate at 37°C for 90 min. Discard the liquid, spin dry, add 100 μL of biotin-labeled creatine kinase isozyme MB antibody working solution to each reaction well, seal the plate and incubate at 37°C for 60 min. Wash, repeat 4 times. Add 100 μL of HRP-labeled streptavidin working solution to each reaction well, seal the plate and incubate at 37°C for 30 min. Wash, repeat 4 times. Add 90 μL of color developer (protected from light) to each reaction well, seal the plate and develop color at 37°C for about 15 min. Add 50 μL of stop solution to each reaction well, and immediately measure the OD value at 450 nm using an enzyme reader. Calculate the average OD value of the standard and sample. Use the "four-parameter logistics model" to draw a standard curve with the concentration of the standard as the horizontal axis and the absorbance OD value as the vertical axis.

[0072] 4.2 Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (FS) testing

[0073] Mice were initially anesthetized in a chamber (2% isoflurane, 95% oxygen, 0.8 L / min) and maintained anesthesia (1.5% isoflurane) in supine position on a 37°C heating pad. Echocardiographic assessments were performed using a Vevo 1100 ultrasound device (visualsonic) and a real-time micro-visualization transducer (MS400, 30 MHz) applied to the shaved chest wall.

[0074] Images were acquired in parasternal long axis, parasternal short axis, and short axis M-mode. Switching to M-mode, the M-mode axis was positioned in the middle layer of the left ventricle. Images of cardiac wall thickness, chamber dimensions, and foreshortening were captured for subsequent measurements. Using the “heart package,” SAX (short axis) parameters were selected and measured, including ventricular septum end diastolic (IVSd), ventricular septum end systolic (IVSs), left ventricular end diastolic value (LVDd), left ventricular end systolic value (LVDs), left ventricular posterior wall end diastolic value (LVPWd), left ventricular posterior wall end systolic value (LVPWs). SAMM images were acquired by placing the M-mode cursor vertically on the parasternal short axis view. Views and data were exported for offline calculations using the dedicated Vevo 1100 quantification software. LV Vol-d (μL; left ventricular diastolic volume), LV Vol-s (μL; left ventricular systolic volume), LV EF (%; left ventricular ejection fraction), FS (%; left ventricular fractional shortening) were measured using SAMM images. All procedures were in accordance with the guidelines for mouse cardiac physiological measurements.

[0075] 4.3 Real-time PCR

[0076] (1) Take out the tissue from the -80°C freezer and place it in an ice box. Use an electronic balance to weigh about 0.02 g of tissue into an EP tube and precool the centrifuge at 4°C.

[0077] (2) Add 1 mL of Trizol and 3 steel beads to the EP tube containing the tissue block, grind with a grinder, remove the liquid, pour out the steel beads, and react at room temperature for 10 min;

[0078] (3) Add 200 μL of chloroform to the EP tube, shake vigorously for 30 seconds, and place on ice for 5-10 minutes;

[0079] (4) After standing, place the centrifuge tube in a 4°C centrifuge at 12,000 rpm for 15 min;

[0080] (5) Pipette the aqueous phase (supernatant) of the centrifuged sample into a new 1.5 mL centrifuge tube;

[0081] (6) Add an equal volume of isopropanol solution to the centrifuged solution, gently invert to mix, and let stand at -20°C for 20 min;

[0082] (7) Take out the sample from -20°C and centrifuge it at 12000 rpm and 4°C for 15 min;

[0083] (8) After centrifugation, discard the supernatant to obtain a white (or colorless and transparent) precipitate. Add 100-300 μL of pre-cooled 75% ethanol prepared with DEPC water along the inner wall of the centrifuge tube and wash 2-3 times.

[0084] (9) After discarding the liquid, air-dry at room temperature for about 15 min. Add 20-50 μL of pre-cooled DEPC water to the centrifuge tube to dissolve the air-dried precipitate (RNA) at the bottom, and store in a -20°C refrigerator until use.

[0085] (10) Use an ultra-micro-volume UV spectrophotometer to measure the RNA concentration, record the results, and calculate the sample loading amount for each group.

[0086] (11) Add the corresponding reaction solution in the reverse transcription kit to premix, add the sample for reverse transcription, shake and centrifuge, place in a PCR instrument, and set the corresponding PCR reaction conditions according to the reverse transcription kit. Store the cDNA sample reverse transcribed by the reverse transcription instrument in a -20°C refrigerator for later use.

[0087] (12) Use a 0.2 mL fluorescent quantitative PCR eight-tube concatenation, add the reactants, use cDNA as a template, use a fluorescent quantitative PCR amplification instrument to amplify the experimental target gene, and perform fluorescent quantitative PCR determination.

[0088] (13) The mixed reactants were shaken and mixed, and after centrifugation, the eight-tube strip was placed in a qRT PCR reactor. The PCR reaction program was set as follows: pre-denaturation: 94°C, 5 min; denaturation: 94°C, 30 s, 60°C, 30 s, 72°C, 30 s, 40 cycles; extension: 72°C, 5 min, and storage at 4°C. The hot cover temperature of the PCR instrument was set to 105°C.

[0089] (14) According to 2 –ΔΔCT The expression changes of target genes were calculated.

[0090] 4.4 Apoptosis detection at mRNA level

[0091] Live cell Caspase-3 activity and Annexin V apoptosis detection kit (Biyuntian Biotechnology, catalog number: C1077S) was used. Accurately weigh the heart tissue, add lysate at a ratio of 100 μL lysate per 3-10 mg tissue, homogenize with a glass homogenizer on an ice bath; transfer the homogenate to a 1.5 mL centrifuge tube, and lyse again on ice for 5 minutes; centrifuge at 16,000-20,000g for 10-15 minutes at 4°C; transfer the supernatant to a centrifuge tube pre-cooled in an ice bath; set up the reaction system, blank control: 40 μL detection buffer, 50 μL lysate, 10 μL Ac-DEVD-pNA (2mM), sample: 40 μL detection buffer, 50 μL sample, 10 μL Ac-DEVD-pNA (2mM). Add the detection buffer first, then the sample to be tested, mix appropriately, and pay attention to avoid bubbles during mixing. Then add Ac-DEVD-pNA (2 mM) and incubate at 37°C for 60-120 minutes. When the color change is obvious, measure A405 and calculate the pNA generated by catalysis in the sample.

[0092] 5. Experimental results and analysis

[0093] like Figure 4 As shown in the figure, the results showed that the serum creatine kinase isoenzyme (CK-MB) content of mice drinking alcohol for a long time was significantly higher than that of mice in the control group. The alcohol group (AF group) had obvious myocardial damage, which means that long-term drinking can cause myocardial damage. The CK-MB content of the AF+Sa01 group and the AF+Sa01 (heat-killed) group was significantly reduced, effectively alleviating myocardial damage. Therefore, Sa01 can significantly reduce the increase of CK-MB caused by alcohol intake.

[0094] from Figure 5 and Figure 6It can be seen that the left ventricular ejection fraction and left ventricular short axis shortening rate of the alcohol group (AF) mice were significantly lower than those of the control group (PF), while the left ventricular ejection fraction and left ventricular short axis shortening rate of the AF+Sa01 group and AF+Sa01(heat-killed) group were significantly higher than those of the AF group. Therefore, it can be judged that the myocardial capacity of the AF group mice was impaired and the cardiac ejection capacity decreased, and ZCMU-Sa01 can effectively restore the myocardial ejection capacity of mice.

[0095] like Figure 7 and Figure 8 As shown in the figure, it is the thickness of the left ventricular posterior wall during diastole and systole. It can be seen from the figure that the thickness of the left ventricular posterior wall of the mice in the alcohol group (AF) is significantly increased compared with the control group (PF), while the thickness of the left ventricular posterior wall of the mice in the AF+Sa01 group and the AF+Sa01 (heat-killed) group is not significantly different from the control group (PF). Therefore, it is judged that ZCMU-Sa01 can effectively reduce the increase in left ventricular wall thickness caused by alcohol in mice and avoid the symptoms of myocardial hypertrophy caused by long-term alcohol intake.

[0096] like Fig. 9 and Fig.10 As shown, it is the heart weight and the ratio of heart to body volume of mice. It can be seen from the figure that the heart weight of mice in the alcohol group (AF) increased, and the ratio of heart to body weight was higher, while the heart weight and heart-to-body ratio of the AF+Sa01 group and AF+Sa01 (heat-killed) group were significantly reduced, and the symptoms of myocardial hypertrophy were restored.

[0097] like Fig.11 and Fig.12 As shown, it is the Bcl2 mRNA level and Bax mRNA level in the mouse heart. It can be seen that the Bcl2 mRNA level in the heart of the alcohol group (AF) mice was significantly lower than that in the control group (PF), while the Bcl2 mRNA level in the heart of the AF+Sa01 group and the AF+Sa01 (heat-killed) group mice was significantly increased compared with the AF group; the Bax mRNA level in the heart of the alcohol group (AF) mice was significantly increased compared with the control group (PF), while the Bax mRNA level in the heart of the AF+Sa01 group and the AF+Sa01 (heat-killed) group mice was significantly decreased compared with the AF group. Therefore, ZCMU-Sa01 is beneficial to the survival of cardiomyocytes.

[0098] It is worth noting that the bacterial liquid of the microacidophilic oligotrophic mononas ZCMU-Sa01 was inactivated (inactivated at 121°C for 30 minutes). As the inactivated ZCMU-Sa01 bacterial liquid, the ZCMU-Sa01 itself has the ability to improve alcoholic cardiomyopathy. The inactivated ZCMU-Sa01 itself can also reduce the level of CK-MB in plasma, restore and increase LVEF and FS, reduce the thickness of the left ventricular wall, reduce the heart weight, increase the expression of cardiac Bcl2 mRNA, and reduce the expression of Bax mRNA. This shows that the bacteria itself has the effect of improving alcoholic cardiomyopathy. Therefore, the inactivated microacidophilic oligotrophic mononas ZCMU-Sa01 can be used as a postbiotic to improve alcoholic cardiomyopathy.

[0099] Example 3 Confirmation of acid resistance and bile resistance of oligotrophomonas microacidophilus ZCMU-Sa01

[0100] 1. Acid resistance test

[0101] A single colony of ZCMU-Sa01 was selected and expanded in LB liquid medium at 37°C for 18 hours. The expanded bacterial suspension was inoculated into LB liquid medium at 1% and cultured at 37°C for 18 hours. The culture solution was centrifuged at 8000r / min for 5 minutes at 4°C to collect the bacteria, and then washed twice with PBS buffer (pH 6.8, 0.1mol / L). The bacteria were suspended in LB liquid medium adjusted to pH 3.0 in advance, and the initial viable count was corrected to about 10 8 CFU / mL (wavelength 600nm, OD=0.5), culture at 37℃ for 24h. Measure the absorbance of the strain at a wavelength of 600nm at 3h, 6h, 12h, and 24h. Measure the survival rate based on the number of live bacteria corresponding to the absorbance at a wavelength of 600nm within 24h.

[0102] The survival rate calculation formula is as follows:

[0103]

[0104] In the above formula, N0 is the viable count of the test strain at 0h (CFU / mL); N t It is the number of viable bacteria (CFU / mL) of the test strain within 24 hours.

[0105] 2. Bile salt tolerance test

[0106] The activated and enlarged suspension of ZCMU-Sa01 was inoculated into LB liquid medium at a volume of 1%, cultured at 37°C for 18 h, vortexed and mixed, and the initial viable count was corrected to about 10 9CFU / mL (wavelength 600nm, OD = 0.5). Inoculate 10% of the strain into LB liquid medium containing 0.3% (m / v) ox bile salt (control is LB liquid medium without ox bile salt), culture at 37°C for 24h, and measure the absorbance of the strain at a wavelength of 600nm at 3h, 6h, 12h, and 24h. The bile salt tolerance of the strain is expressed as the logarithm of the difference between the number of viable bacteria per milliliter of the medium containing bile salts and the number of viable bacteria per milliliter of the medium without bile salts at 24h (log CFU / mL), and the number of viable bacteria corresponds to its absorbance value at a wavelength of 600nm.

[0107] As shown in Table 2, the survival rate of ZCMU-Sa01 in LB medium with a pH of 3.0 was as high as 96.05%. The number of viable bacteria still reached 10 in an environment containing 0.3% ox bile salt. 8 CFU / mL or more indicates that it has good bile salt tolerance. Experiments have shown that ZCMU-Sa01 has a high gastrointestinal survival ability.

[0108] Table 2 Results of strain tolerance to acid and bile salts

[0109]

[0110] Probiotics must be able to survive a series of adverse environments such as gastric acid and bile in the gastrointestinal tract to play their probiotic effects. The microacidophilic oligotrophic mononas ZCMU-Sa01 provided by the present invention can grow and proliferate under the condition of pH 3.0, and can smoothly pass through the acidic environment in the stomach to reach the small intestine. At the same time, the microacidophilic oligotrophic mononas ZCMU-Sa01 can tolerate bile salts, and it can survive in the intestine, thereby effectively improving the intestinal flora and playing a hypoglycemic effect.

[0111] Example 4 Confirmation of Antibiotic Susceptibility of Oligotrophomonas microacidophilus ZCMU-Sa01

[0112] The concentration of the cultured cells after 18 hours is about 10 7 Add 1% of CFU / mL of the microacidophilic oligotrophic monocytogenes ZCMU-Sa01 bacterial suspension to the sterilized LB agar medium cooled to about 45°C, mix thoroughly, and add 15mL / dish quantitatively. After solidification, use tweezers to take the drug-sensitive paper and place it on the culture medium. Place the culture dish face up in a 37°C incubator and culture for 24 hours. Use the paper without antibiotics as a blank control. Measure the diameter of the inhibition zone. Repeat each three times.

[0113] The diameter of the inhibition zone of the sensitivity of microacidophilic oligotrophic mononas ZCMU-Sa01 to antibiotics is shown in Table 3. According to the CLSI (2017) drug sensitivity test standard, microacidophilic oligotrophic mononas ZCMU-Sa01 is sensitive to gentamicin, erythromycin, ciprofloxacin and chloramphenicol. It is intermediate for ampicillin and clindamycin. The experimental results show that microacidophilic oligotrophic mononas ZCMU-Sa01 is sensitive to common antibiotics.

[0114] Table 3 Results of antibiotic sensitivity of Oligotrophomonas microacidophilus ZCMU-Sa01

[0115]

[0116] Note: S, sensitive; I, intermediate; R, resistant.

[0117] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Acidophilus oligotrophicum ( Stenotrophomonas acidaminiphila ) or its related products in the preparation of a drug for improving alcoholic cardiomyopathy, characterized in that: The related product is the fermentation liquid, inactivated bacterial cells or bacterial suspension of the microacidophilic oligotrophic monosporus; the preservation number of the microacidophilic oligotrophic monosporus is CGMCC No.26919.

2. A fermentation method of oligotrophic microacidophilus, characterized in that: The microacidophilic oligotrophic mononas is inoculated into LB liquid culture medium and cultured at 37° C. for 18 to 24 hours; the deposit number of the microacidophilic oligotrophic mononas is CGMCC No. 26919.